No sector of the healthcare industry is rooting harder for the Supreme Court to overturn the Affordable Care Act completely tomorrow than are medical device companies, which are bracing themselves for a substantial excise tax on their revenues that takes effect next year under the law.
Obamacare reconsidered: a pretty good deal for the drug industry
As the Supreme Court weighs the constitutionality of the Patient Protection and Affordable Care Act’s “Individual Mandate”—and maybe the law itself—a pretty sweet deal for the drug industry hangs in the balance.